PD-1/PD-L1 inhibitors alone quickly develop drug resistance; combining with chemotherapy can enhance anti-tumor immunity by inducing immunogenic cell death, improving efficacy, and delaying the onset of drug resistance (2, 11, 12). Here, PDCD1 is linked to neoplasm.